Regeneron Pharmaceuticals Inc (WBO:REGN)
€ 757.4 -20.4 (-2.62%) Market Cap: 83.82 Bil Enterprise Value: 77.30 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 99/100

Regeneron Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 15, 2022 / 02:00PM GMT
Release Date Price: €608.2 (+1.21%)
Hartaj Singh
Oppenheimer & Co. Inc., Research Division - Research Analyst

Great. Thank you, Andrew. Really appreciate it. Thanks for helping set this up and making it so easy. Hi, everybody. We're getting to the middle or close to the middle part of the day in the first day of the Oppenheimer Healthcare Conference. We have Regeneron also presenting at this fireside chat. Representing Regeneron is Dr. Izzy Lowy, who is the Head of Translational and Clinical Oncology at Regeneron. I'm sure quite a few have heard him speak before at various investor events. I have also. So it's a real pleasure to have you with us today, Dr. Lowy. Really appreciate it.

Israel Lowy
Regeneron Pharmaceuticals, Inc. - SVP of Translational & Clinical Sciences - Oncology

Well, thank you very much. It's a pleasure to be here, and I hope I can answer your questions and give information that's useful for investors for understanding our pipeline at Regeneron.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot